

RECEIVED

CENTRAL FAX CENTER

Docket No. 27693-01201

OCT 19 2004 U.S. Patent Application No. 09/436,347

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of Christine A. WHITE et al.	Examiner: Alana M. Harris
Serial No. 09/436,347	Docket No.: 27693-01201
Filed: November 9, 1999	Group Art Unit: 1642
For: TREATMENT OF HEMATOLOGIC MALIGNANCIES ASSOCIATED WITH CIRCULATING TUMOR CELLS USING CHIMERIC ANTI-CD20 ANTIBODY	

Hon. Commissioner of Patents and Trademarks  
 U.S. Patent and Trademark Office  
 2011 South Clark Place  
 Customer Window, Mail Stop Patent Application  
 Crystal City Plaza Two, Lobby, Room 1B03  
 Arlington, VA 22202

Sir:

Listed on the accompanying Form PTO-1449 is a document that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that an exhaustive search has been made, or that there does not exist information more material to the examination of the present patent application. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will review art of record in all 35 U.S.C. § 120 priority documents.

Docket No. 27693-01201

U.S. Patent Application No. 09/436,347


1.  The Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.

a)  We hereby authorize the amount of \$180.00 in payment of the fee under 37 C.F.R. § 1.17(p) to be charged to Sidley Austin Brown & Wood LLP's Deposit Account No. 18-1260.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and to indicate in the official file wrapper of this patent application that the document has been considered.

If Applicant has overlooked the payment of any fees with regard to the filing of this Information Disclosure Statement, the Commissioner is hereby authorized to charge Deposit Account No. 18-1260.

Respectfully submitted,



Jeffrey P. Kushan  
Reg. No. 43,401  
Attorney for Applicant

SIDLEY AUSTIN BROWN & WOOD LLP  
1501 K Street, N.W.  
Washington, DC 20005  
202-736-8000

Dated: October 19, 2004  
JKP/SEP/yea  
Enclosures

<b>INFORMATION DISCLOSURE STATEMENT</b>	Docket No.	27693-1201	Application No. 09/436,347
	Applicant(s):	Christine A. WHITE et al.	Examiner: Abuz M. Harris
	Filing Date:	November 9, 1999	Group Art Unit: 1642

U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

McLaughlin, P. et al. "Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program." *Journal of Clinical Oncology*, Vol. 16, No. 8, August 1998, pp. 2825-2833.

EXAMINER / Alana M. Harris / DATE CONSIDERED April 11, 2006  
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609;  
Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
Form PTO-A820 (also form PTO-1449) SHEET 1 OF 1